An antibody in our portfolio was recently licensed non-exclusively to a fully commercial antibody franchise situated in the US for incorporaiton into their catalogue of products available for purhase for research use only. The license agreement included a signing-fee and royalty on net sales of products.
An expression vector was licensed to a clinical research organisation in Europe for them to subsequent establish an internal assay of the protein product to offer as an analytical service towards the pharma industry. The license agreement included a signing-fee and royalty on net income of services.
A transgenic mouse model was licensed to a pharmaceutical company in the US to be used in internal selection, research and development of their drug candidates. The non-exclusive license including a signing-fee and an annual rental fee.
A batch of protein was sold and shipped to a biotech company in Asia to be used in their IND regulatory approval process for a new compound related to cancer treatment. The license included a one-time fee.
A stable cell line was non-exclusively licensed to a US based biotech company to be used in their internal research and development. The non-exclusive license including a one-time signing-fee.